Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100932 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00100932: Completed Phase 2 study, sponsored by Eisai.
NCT00100932 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 106 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100932, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a study of E7389 in patients with recurrent and/or metastatic Non-Small-Cell Lung Cancer (NSCLC) who progressed during or after treatment with a platinum agent and another chemotherapy.
Primary Outcome
Based on Response Evaluation Criteria in Solid Tumors (RECIST), consisting of complete response (CR) plus partial response (PR). Defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diame
Interventions
- DRUG E7389 28 Day Cycle
- DRUG E7389 21 Day Cycle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00100932 record still lists
NCT00100932 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which E7389 28 Day Cycle is the first listed.
NCT00100932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00100932 about?
NCT00100932 is a clinical study titled "Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy". This is a study of E7389 in patients with recurrent and/or metastatic Non-Small-Cell Lung Cancer (NSCLC) who progressed during or after treatment with a platinum agent and another chemotherapy.
What is the current status of trial NCT00100932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2004-12.
What interventions are being tested in trial NCT00100932?
The interventions under investigation include: E7389 28 Day Cycle (DRUG), E7389 21 Day Cycle (DRUG).
Who is sponsoring clinical trial NCT00100932?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00100932's enrollment target sits among peer trials
106 648th of 2000 higher than 1,351 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia